您好, 歡迎來(lái)到化工儀器網(wǎng)
產(chǎn)品簡(jiǎn)介
詳細(xì)介紹
溫馨提示:優(yōu)寧維所有產(chǎn)品和服務(wù)僅用于科學(xué)研究,不用于臨床等診斷及其他用途提供產(chǎn)品和服務(wù)(也不為任何個(gè)人提供產(chǎn)品和服務(wù))!
| 反應(yīng)性 | H |
| 靈敏度 | 內(nèi)源性 |
| MW (kDa) | 40-50 |
| 來(lái)源/同種型 | 兔 IgG |
應(yīng)用關(guān)鍵詞:
- WB- 蛋白質(zhì)印跡法
- IP-免疫沉淀法
- IHC-免疫組織化學(xué)法
- ChIP-染色質(zhì)免疫沉淀法
- IF-免疫熒光法
- F-流式細(xì)胞術(shù)
- E-P-ELISA 肽
物種交叉反應(yīng)性關(guān)鍵詞:
- H-人
- M-小鼠
- R-大鼠
- Hm- 倉(cāng)鼠
- Mk-猴
- Vir- 病毒
- Mi-水貂
- C-雞
- Dm-黑腹果蠅
- X-爪蟾
- Z-斑馬魚
- B-牛
- DG-犬
- PG-豬
- Sc-釀酒酵母
- Ce-秀麗隱桿線蟲
- Hr-馬
- All-預(yù)期所有物種
產(chǎn)品使用信息
| 應(yīng)用 | 稀釋度 |
|---|---|
| 蛋白質(zhì)印跡法 | 1:1000 |
| 免疫沉淀法 | 1:50 |
| IHC-Leica® Bond™ | 1:200 - 1:800 |
| 免疫組織化學(xué)(石蠟) | 1:100 - 1:400 |
| 流式細(xì)胞術(shù) | 1:200 - 1:800 |
保存
保存在 10 mM sodium HEPES (pH 7.5)、150 mM NaCl、100 μg/ml BSA、50% 甘油和低于 0.02% 的中。-20℃ 保存。切勿分裝抗體。
特異性/靈敏度
PD-L1 (E1L3N®) XP® Rabbit mAb 可識(shí)別內(nèi)源水平的 PD-L1 總蛋白。物種反應(yīng)性:
人
來(lái)源/純化
使用與人 PD-L1 蛋白中羧基末端周圍的殘基相對(duì)應(yīng)的合成肽,對(duì)動(dòng)物進(jìn)行免疫接種來(lái)產(chǎn)生單克隆抗體。
背景
Programmed cell death protein 1 ligａnd 1 (PD-L1, B7-H1, CD274) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The PD-L1 ligａnd binds to the PD-1 transmembrane receptor and inhibits T cell activation. PD-L1 was discovered after many B7 protein homologues were found, and it was later shown to be expressed in antigen-presenting cells, activated T cells, and tissues such as placenta, heart, and lung (1-3). PD-L1 is structurally similar to B7 family members in that it contains extracellular IgV and IgC domains and a short cytoplasmic region. Studies have shown that PD-L1 is expressed in cells of many tumor types including melanoma, ovarian, colon, lung, breast and renal cell carcinomas (4-6). PD-L1 expression in cancer cells is associated with tumor-infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma (7). Other studies have implicated PD-L1 expression in viral infection-related cancers (8,9).- Dong, H. et al. (1999) Nat Med 5, 1365-9.
- Freeman, GJ et al. (2000) J Exp Med 192, 1027-34.
- Liang, SC et al. (2003) Eur J Immunol 33, 2706-16.
- Dong, H. et al. (2002) Nat Med 8, 793-800.
- Thompson, RH et al. (2006) Cancer Res 66, 3381-5.
- Pardoll, DM (2012) Nat Rev Cancer 12, 252-64.
- Taube, JM et al. (2012) Sci Transl Med 4, 127ra37.
- Lyford-Pike, S. et al. (2013) Cancer Res 73, 1733-41.
- Chen, BJ et al. (2013) Clin Cancer Res 19, 3462-73.
- Wimberly, H. et al. (2014) Cancer Immunol Res ,
